EVAX vs. ZIVO, APTO, AIM, SNTI, PMCB, BCLI, TVGN, CRTX, COEP, and NKGN
Should you be buying Evaxion Biotech A/S stock or one of its competitors? The main competitors of Evaxion Biotech A/S include ZIVO Bioscience (ZIVO), Aptose Biosciences (APTO), AIM ImmunoTech (AIM), Senti Biosciences (SNTI), PharmaCyte Biotech (PMCB), Brainstorm Cell Therapeutics (BCLI), Tevogen Bio (TVGN), Cortexyme (CRTX), Coeptis Therapeutics (COEP), and NKGen Biotech (NKGN). These companies are all part of the "medical" sector.
Evaxion Biotech A/S (NASDAQ:EVAX) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, media sentiment, analyst recommendations, community ranking and profitability.
Evaxion Biotech A/S has a beta of -0.22, indicating that its share price is 122% less volatile than the S&P 500. Comparatively, ZIVO Bioscience has a beta of 0.26, indicating that its share price is 74% less volatile than the S&P 500.
ZIVO Bioscience has lower revenue, but higher earnings than Evaxion Biotech A/S. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Evaxion Biotech A/S, indicating that it is currently the more affordable of the two stocks.
Evaxion Biotech A/S has a net margin of 0.00% compared to ZIVO Bioscience's net margin of -11,068.75%. ZIVO Bioscience's return on equity of 0.00% beat Evaxion Biotech A/S's return on equity.
ZIVO Bioscience received 82 more outperform votes than Evaxion Biotech A/S when rated by MarketBeat users. Likewise, 61.11% of users gave ZIVO Bioscience an outperform vote while only 56.67% of users gave Evaxion Biotech A/S an outperform vote.
In the previous week, Evaxion Biotech A/S had 2 more articles in the media than ZIVO Bioscience. MarketBeat recorded 4 mentions for Evaxion Biotech A/S and 2 mentions for ZIVO Bioscience. ZIVO Bioscience's average media sentiment score of 1.38 beat Evaxion Biotech A/S's score of 0.22 indicating that ZIVO Bioscience is being referred to more favorably in the news media.
11.0% of Evaxion Biotech A/S shares are held by institutional investors. Comparatively, 12.8% of ZIVO Bioscience shares are held by institutional investors. 41.6% of Evaxion Biotech A/S shares are held by company insiders. Comparatively, 13.4% of ZIVO Bioscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Evaxion Biotech A/S currently has a consensus target price of $11.00, indicating a potential upside of 183.51%. Given Evaxion Biotech A/S's higher probable upside, research analysts clearly believe Evaxion Biotech A/S is more favorable than ZIVO Bioscience.
Summary
ZIVO Bioscience beats Evaxion Biotech A/S on 9 of the 17 factors compared between the two stocks.
Get Evaxion Biotech A/S News Delivered to You Automatically
Sign up to receive the latest news and ratings for EVAX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EVAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Evaxion Biotech A/S Competitors List
Related Companies and Tools